Friday, February 15, 2019

ProMIS Neurosciences (PMN:CA)

ProMIS Initiation Report.

ProMIS Neurosciences,
Inc., a development stage biotech company, discovers and develops precision
medicine therapeutics for the treatment of neurodegenerative diseases,
primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Its
proprietary target discovery engine is based on the use of two complementary
techniques. 

Cosme Ordoñez, M.D., Ph. D.

, Life Sciences Analyst, Noble Capital Markets, Inc.

RATING: OUTPERFORM

• Coverage initiation. We are initiating coverage on ProMIS Neurosciences, Inc. with an Outperform Rating and a $1.00 target price. 
• A unique technology. ProMIS has developed a unique technology to identify disease specific conformational epitopes, which allows the Company to discover antibodies targeting neurodegenerative diseases such as Alzhei…
  
  
  GO TO FULL REPORT
  
  
  

  
  Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.